S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:MGTA

Magenta Therapeutics - MGTA Stock Forecast, Price & News

$0.46
+0.02 (+4.52%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.43
$0.48
50-Day Range
$0.36
$1.33
52-Week Range
$0.32
$3.62
Volume
932,225 shs
Average Volume
1.39 million shs
Market Capitalization
$27.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.33

Magenta Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
837.7% Upside
$4.33 Price Target
Short Interest
Healthy
1.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
-0.45mentions of Magenta Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

144th out of 1,055 stocks

Pharmaceutical Preparations Industry

61st out of 519 stocks


MGTA stock logo

About Magenta Therapeutics (NASDAQ:MGTA) Stock

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA.

Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Short Volatility Alert: Magenta Therapeutics
BTIG Reaffirms Their Buy Rating on Magenta Therapeutics (MGTA)
Recap: Magenta Therapeutics Q3 Earnings
Magenta Therapeutics, Inc. (MGTA)
Magenta Therapeutics GAAP EPS of -$0.39
See More Headlines
Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTA
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+837.7%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-71,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.94 per share

Miscellaneous

Free Float
51,364,000
Market Cap
$27.98 million
Optionable
Not Optionable
Beta
2.12

Key Executives

  • Jason Gardner
    President, Chief Executive Officer & Director
  • Stephen Frank Mahoney
    COO, CFO, Treasurer & Chief Accounting Officer
  • Lisa M. Olson
    Chief Scientific Officer & Head-Research
  • David Nichols
    Chief Technical Officer
  • Jeffrey S. Humphrey
    Chief Medical Officer













MGTA Stock - Frequently Asked Questions

Should I buy or sell Magenta Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares.
View MGTA analyst ratings
or view top-rated stocks.

What is Magenta Therapeutics' stock price forecast for 2023?

5 analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their MGTA share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 837.7% from the stock's current price.
View analysts price targets for MGTA
or view top-rated stocks among Wall Street analysts.

How have MGTA shares performed in 2023?

Magenta Therapeutics' stock was trading at $0.3950 at the beginning of the year. Since then, MGTA stock has increased by 17.0% and is now trading at $0.4621.
View the best growth stocks for 2023 here
.

When is Magenta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our MGTA earnings forecast
.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04.

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hellman Jordan Management Co. Inc. MA (0.73%). Insiders that own company stock include Bruce Booth and Kristen Stants.
View institutional ownership trends
.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $0.46.

How much money does Magenta Therapeutics make?

Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $27.98 million. The company earns $-71,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 242-0170 or via email at investor@magentatx.com.

This page (NASDAQ:MGTA) was last updated on 1/28/2023 by MarketBeat.com Staff